title: Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking.
abstract: Over the last decade there have been significant advances in the discovery and understanding of the cannabinoid system along with the development of pharmacologic tools that modulate its function. Characterization of the crosstalk between nicotine addiction and the cannabinoid system may have significant implications on our understanding of the neurobiological mechanisms underlying nicotine dependence. Two types of cannabinoid receptors (CB1 and CB2) have been identified. CB1 receptors are expressed in the brain and modulate drug taking and drug seeking for various drugs of abuse, including nicotine. CB2 receptors have been recently identified in the brain and have been proposed to play a functional role in mental disorders and drug addiction. Our objective was to explore the role of CB2 receptors on intravenous nicotine self administration under two schedules of reinforcement (fixed and progressive ratio) and on nicotine seeking induced by nicotine priming or by nicotine associated cues. For this, we evaluated the effects of various doses of the selective CB2 antagonist AM630 (1.25 to 5 mg/kg) and CB2 agonist AM1241 (1 to 10 mg/kg) on these behavioral responses in rats. Different groups of male Long Evans rats were trained to lever press for nicotine at a unit dose of 30 µg/kg/infusion. Subsequently, animals were randomized using a Latin-square design and injected with either AM1241 or AM630 using a counterbalanced within subject design. Administration of the CB2 ligands did not affect either nicotine-taking nicotine-seeking behavior. Our results do not support the involvement of CB2 receptors in nicotine-taking or nicotine-seeking behavior.
authors.affiliation: Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Canada.
authors.forename: Islam
authors.initials: I
authors.lastname: Gamaleddin
authors.forename: Alexander
authors.initials: A
authors.lastname: Zvonok
authors.forename: Alexandros
authors.initials: A
authors.lastname: Makriyannis
authors.forename: Steven R
authors.initials: SR
authors.lastname: Goldberg
authors.forename: Bernard
authors.initials: B
authors.lastname: Le Foll
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002186:Cannabinoids / Q000494:pharmacology; D003216:Conditioning, Operant; D058999:Drug-Seeking Behavior / Q000187:drug effects* / Q000502:physiology; D007211:Indoles / Q000494:pharmacology*; D007275:Injections, Intravenous; D008297:Male; D009538:Nicotine / Q000008:administration & dosage*; D051381:Rats; D020318:Rats, Long-Evans; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000037:antagonists & inhibitors; D012008:Recurrence; D012054:Reinforcement, Psychology; D012646:Self Administration; D013379:Substrate Specificity / Q000187:drug effects; D014029:Tobacco Use Disorder / Q000473:pathology / Q000523:psychology*
chemical_list: C439263:AM 1241; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D007211:Indoles; D043885:Receptor, Cannabinoid, CB2; D009538:Nicotine; C094023:iodopravadoline